STADOVAS 10 Tablet
ក្រុមហ៊ុនផលិតឱសថ:
STADA-VN J.V. Co., Ltd., Vietnam
- សារធាតុសកម្ម
- ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
- ហាមប្រើ
- ផលរំខាន
- អន្តរប្រតិកម្ម
- ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន
- ការប្រុងប្រយ័ត្នជាពិសេស
- សកម្មភាពឱសថ បរិយាយប័ណ្ណឱសថ
-
សារធាតុសកម្ម
Amlodipine 10mg
-
ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
- Amlodipine is used alone or in combination with other classes of antihypertensive agents in the management of hypertension.
- For the management of Prinzmetal variant angina and chronic stable angina pectoris. The drug has been used alone or in combination with other antianginal agents.
Dosage and Administration
Orally and may be given without regard to meals.
Dosage
- For both hypertension and angina the usual initial dose is 5mg amlodipine once daily which may be increased to a maximum dose of 10mg depending to the individual patient’s response.
- No dose adjustment of amlodipine is required upon concomitant administration of thiazide diuretics, beta-blockers, and angiotensin-converting enzyme inhibitors.
- Use in the elderly normal dosage regimens are recommended. Amlodipine, used at similar doses in elderly or younger patients, is equally well tolerated. Use in children safety and effectiveness of amlodipine in children have not been established.
-
ហាមប្រើ
Patients who are hypersensitive to amlodipine, to any other calcium antagonist, or any ingredient in the formulation.
-
ផលរំខាន
The most common adverse effects of amlodipine are associated with its vasodilator action and often diminish on continued therapy. They include dizziness, flushing, headache, hypotension, peripheral oedema, tachycardia, and palpitations. Nausea and other gastrointestinal disturbances, increased micturition frequency, lethargy, eye pain, visual disturbances, and mental depression have also occurred. A paradoxical increase in ischaemic chest pain may occur at the start of treatment and in a few patients excessive fall in blood pressure has led to cerebral or myocardial ischaemia or transient blindness.
-
អន្តរប្រតិកម្ម
See the package insert about the details below:
- Amlodipine has been safely administered with thiazide diuretics, alpha blockers, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual glyceryl trinitrate, NSAIDs, antibiotics, and oral hypoglycaemic drugs.
- Cimetidine, grapefruit juice, antacid
- Sildenafil
- Atorvastatin, ethanol (alcohol)
- Digoxin
-
ស្ត្រីមានផ្ទៃពោះ និង ស្ត្រីបំបៅដោះកូន
No clinical experience with the preparation in pregnancy or lactation.
Accordingly, amlodipine should not be administered during pregnancy, or lactation, or to women of childbearing potential unless effective contraception is used.
-
ការប្រុងប្រយ័ត្នជាពិសេស
- Amlodipine should be used with caution in patients with hypotension, cardiac reserve is poor, heart failure.
- The drug should not be used in cardiogenic shock, in patients who have suffered a myocardial infarction in the previous 2-4 weeks, or in acute unstable angina, in treatment an anginal attack in chronic stable angina.
- In patients with severe aortic stenosis amlodipine may increase the risk of developing heart failure. Sudden withdrawal of amlodipine might be associated with an exacerbation of angina.
- The dose may need to be reduced in patients with hepatic impairment.
-
សកម្មភាពឱសថ
Amlodipine is a dihydropyridine calcium antagonist (calcium ion antagonist or slow channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels.
Amlodipine inhibits calcium ion flux across cell membranes selectively, with a greater effect on vascular smooth muscle cells than on cardiac muscle cells. Amlodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.
*ព័ត៌មានឱសថត្រូវបានរៀបរៀងដោយ អ៊ីម៉ាតុគឹ មេឌីក (ខេមបូឌា) ដោយផ្អែកលើប្រភពព័ត៌មានខាងក្រោម។ សម្រាប់ព័ត៌មានលម្អិត សូមស្វែងរកនៅក្នុងក្រដាសព័ត៌មាននៃឱសថនីមួយៗ ឬ សាកសួរទៅកាន់ក្រុមហ៊ុនឱសថឬតំណាងចែកចាយនៃឱសថនីមួយៗ។
ប្រភពព័ត៌មាន៖
- ក្រដាសព័ត៌មាននៃឱសថសម្រាប់អ្នកជំនាញវេជ្ជសាស្ត្រដែលប្រើប្រាស់នៅប្រទេសជប៉ុន (Pharmaceutical and Medical Devices Agency, Pmda): https://www.pmda.go.jp
- ព័ត៌មានសង្ខេបនៃឱសថសម្រាប់អ្នកជំងឺដែលប្រើប្រាស់នៅប្រទេសជប៉ុន: http://www.rad-ar.or.jp